Citations

Clear

6274 citation(s) found for "Ng, Andrew".

Systematic Review Supporting the American Society of Hematology Practice Guidelines on the Management of Myelofibrosis
Hasan, Bashar , Fleti, Farah , Taki Aldin, Sameh , Moustafa, Amr , Tabiim, Anthony J, Chaaban, Mohammad Karam , Tremblay, Douglas , Vannucchi, Alessandro M , Abdallah, Maya M , Gupta, Vikas , Srisuwananukorn, Andrew , Murad, M Hassan

Mayo Clinic

Blood Advances | November 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021619 | PMID 43063918 Get It

Myelofibrosis (MF) is a Philadelphia-negative clonal disorder of hematopoietic stem cells associated with substantial clinical practice variation. The American Society of Hematology (ASH) convened a guideline panel that prioritized ten clinical questions to inform evidence-based recommendations. We performed a comprehensive systematic review of MEDLINE, EMBASE, Cochrane databases, and Scopus through January 2025 to identify studies that addressed the ten clinical questions. Meta-analyses were performed where feasible. Two reviewers independently selected and appraised studies. Certainty of evidence was assessed using GRADE. Of 3,007 records screened, 43 unique studies met inclusion criteria for the ten questions. Extended molecular testing identified high-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2) that were significantly associated with decreased overall survival (hazard ratios ranging 1.5-4.5). JAK inhibitors improved spleen and symptom responses in symptomatic lower-risk MF and in patients with anemia, with momelotinib improving transfusion independence. However, survival effects were not clearly demonstrated and hematologic toxicity remained common. Evidence for treating asymptomatic high-risk patients with JAK inhibitors was particularly limited. Early allogeneic hematopoietic cell transplantation was associated with higher early mortality but improved long-term survival compared with delayed transplantation. Pretransplant JAK inhibitor exposure did not significantly affect mortality, GVHD, or graft failure. Evidence for interferon, aspirin, and iron chelation was limited and largely indirect. The certainty of evidence was very low or low across nearly all outcomes.
Infective endocarditis after heart transplantation: clinical characteristics and outcomes
Hindy, Joya-Rita , McHugh, Jack W., Rosenbaum, Andrew N , Baddour, Larry

Mayo Clinic

Infectious Diseases | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1080/23744235.2026.2764153 | PMID 43049132 Get It

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Evaluation of the DISQVER metagenomic sequencing platform for detection of microbial cell-free DNA in plasma and cerebrospinal fluid
Cox, Christina R , Norgan, Andrew P , Yao, Joseph D. , Patel, Robin , Simner, Patricia J

Mayo Clinic

Journal of Clinical Microbiology | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1128/jcm.01037-26 | PMID 43012523 Get It

CYCLIC LOCAL ANTIBIOTIC IRRIGATION TO TREAT PERIPROSTHETIC JOINT INFECTION: 24-MONTH TREATMENT OUTCOMES FROM TWO PROSPECTIVE, RANDOMIZED TRIALS
Piuzzi, Nicolas, de Beaubien, Brian, Higuera, Carlos A. , Glassman, Andrew , Parvataneni, Hari , Urish, Kenneth L. , Springer, Bryan D.

Mayo Clinic

Orthopaedic Proceedings | November 6, 2026 | Volume: 108-B | Issue: SUPP_11 | Pages: 63-63

10.1302/1358-992x.2026.11.063 Get It

Introduction and Aim Periprosthetic joint infection (PJI) remains one of the most devastating complications following total joint arthroplasty, and a leading indication for revision surgery. As the incidence of PJI continues to rise, treatment outcomes remain constrained by sub-optimal standard-of-care treatment options. We conducted two prospective, randomized, multi-center, FDA-regulated clinical trials evaluating a novel PJI treatment* that uses cyclic, local, antibiotic irrigation to deliver high concentrations of vancomycin and tobramycin directly to the infected joint. Methods Patients with chronic hip or knee PJI were randomized to receive the CLEAR (cyclic, local, expedited, antibiotic-irrigation regimen) protocol with drug and device combination product* (CLEAR) or two-stage exchange arthroplasty (control) and followed for 24 months. CLEAR patients received 7 days of intra-articular cyclic irrigation with 80 mg tobramycin once daily, then hourly irrigation with 125 mg of vancomycin. The primary outcome was treatment success following explantation of the infected prosthesis, defined as infection control without suppressive antibiotics. Infection control included permanent prosthesis reimplantation, absence of reoperation, absence of PJI, and survival. Secondary outcomes included reimplantation rate, time to reimplantation, operative time, septic revision rate, and mortality. Results A total of 152 randomized patients underwent explantation [CLEAR: 76 patients; mean age: 67.0, 42.1% female, 89.5% White, mean BMI: 31.8, 56.6% knee; Control: 76 patients; mean age: 65.3, 32.9% female, 90.8% White, mean BMI: 34.0, 63.2% knee], of which 141 (93.0%) completed the 24-month assessment. At 24 months, 74.0% of patients (51/69) in the CLEAR group achieved treatment success compared to 51.4% in the control (37/72; significant nominal p=0.0058). Reimplantation rates were higher with the CLEAR protocol (100% vs. 87%), mean time to reimplantation was markedly shorter (7 vs. 127 days), and mean total operative time in the explant and reimplant surgeries was shorter (304 min vs 363 min). The control group experienced 83% more unplanned septic reoperations through 24 months (22 vs 12). The mortality rate at 24 months was higher in the control group (9.7% vs 7.2%). Conclusions The CLEAR protocol with the drug and device combination product* demonstrated superior outcomes at 24 months compared to two-stage exchange for chronic PJI. More patients treated using the CLEAR protocol with the drug and device combination product* received a permanent prosthesis, in a significantly shorter time, and more achieved treatment success, with shorter total operative time and fewer unplanned septic reoperations. These findings support the CLEAR protocol with the drug and device combination product* as a promising therapeutic strategy for the treatment of chronic PJI. * VT-X7 (Osteal Therapeutics)
Overlooked Writings of Sir William Gowers on Neurology in General Practice, Shorthand, and Education
Rogers, Nathaniel , Lees, Andrew John , Boes, Christopher J.

Mayo Clinic

Neurology | November 6, 2026 | Volume: 107 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000218701 | PMID 42993914 Get It

Frequency and Phenotype of Coexisting Aquaporin‐4 and Autoimmune Encephalitis Autoantibodies
Cacciaguerra, Laura , Yang, Binxia, Lennon, Vanda A. , Agnihotri, Shruti P. , Ahsan, Nusrat , Fernández, Karen S. , McLeod, Erin, Mangioris, Georgios , Meador, William R., Mitchell, Wendy G. , Nicholas, Jacqueline A. , Quek, Amy M.L. , Shoemaker, Thomas , Sieloff, Kurt, Edmond, Matt C., Laggis, Rebekah A., Flynn, Kristin L., Waubant, Emmanuelle L. , Chen, John J., Irani, Sarosh R. , McKeon, Andrew , Ζεκερίδου, Αναστασία , Flanagan, Eoin P. , Pittock, Sean J. , Kunchok, Amy

Mayo Clinic

Annals of Clinical and Translational Neurology | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70541 | PMID 42979782 Get It

ABSTRACT Among 9457 aquaporin‐4 (AQP4) immunoglobulin G‐positive patients, 2071 underwent autoimmune encephalitis antibody testing and 85 (4%) had coexisting antibodies, most commonly cerebrospinal fluid glial fibrillary acidic protein‐IgG and N‐methyl‐D‐aspartate receptor‐IgG, or serum high‐titer GAD65‐IgG. Compared with AQP4‐IgG positive neuromyelitis optica spectrum disorder controls, dual‐positive patients were younger and more frequently exhibited encephalopathy, psychiatric symptoms, seizures, ovarian teratomas, and deep gray matter, temporal lobe, or diencephalic MRI abnormalities. GAD65‐IgG‐positive patients developed stiff‐person syndrome. These findings define a distinct mixed glial‐neuronal autoimmune phenotype and support additional neural antibody testing in atypical AQP4‐IgG‐positive presentations.
Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases
Herman, Max Charles , Marzello, Maya, Tharwani, Zoaib Habib, Kotaru, Snigdha , Day, Gregory S , McKeon, Andrew , Lopez-Chiriboga, A Sebastian , Irani, Sarosh R

Mayo Clinic

Annals of Clinical and Translational Neurology | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70578 | PMID 42974934 Get It

ABSTRACT Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of paraclinical parameters compared in discovery and validation cohorts. CSF GAD65‐antibody titers ≥ 1 nmol/L performed best in discovery (AUC 0.956) and validation (AUC 0.949; p = 0.814), with 89.7% sensitivity and 94% specificity for identifying tGAD65. Serum titers > 20 nmol/L and indices of intrathecal synthesis showed lower discriminative ability. Our finding aims to reduce misdiagnosis and identify potential immunotherapy‐responsive diseases.
Legal, Regulatory, and Claims-Related Factors Associated With U.S. General Surgery Malpractice Premiums, 2013-2023
Saleeb, Andrew G , Sioda, Natasha A. , Cheung, Dillon C , Nelson, Megan, Jorge, Irving A

Mayo Clinic

The American Surgeon™ | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261505262 | PMID 42975981 Get It

Background General surgery malpractice premiums vary across states. We examined whether legal, regulatory, and payment measures were associated with premium levels and annual changes. Methods We analyzed 50 states during 2013-2023, expressing monetary measures in 2023 dollars. Between-state regressions evaluated mean premiums; annual models included state- and year-fixed effects. Generalized caps included restrictions on noneconomic recovery in at least one ordinary medical-liability claim category. Policy-change analyses were exploratory. Results Among 550 state-years, each additional mean annual payment report per million residents was associated with 2.32% higher mean premiums across states (95% CI, 1.20%-3.44%; P < .001). The adjusted cap association was −18.53% (95% CI, −37.11% to 5.53%; P = .118); judicial climate and premium regulation were also nonsignificant. Within-state payment-frequency and payment-size associations were nonsignificant. Three states changed generalized cap status; event-time estimates showed pre-change differences (joint P = .016), limiting causal interpretation. Discussion Higher payment frequency was associated with higher average premiums across states, but year-to-year changes in payment frequency within a given state were not detectably associated with that state’s own premium changes. Cap estimates varied depending on how caps were defined and remained statistically uncertain. These ecological findings do not establish causal effects or support specific policy prescriptions.
Multi-omics in the All Of Us Research Program expands mapping genetic mechanisms in health and disease
Marderstein, Andrew R.

Mayo Clinic

No container title available | November 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.29.26366507 Get It

The All of Us (AoU) Research Program multi-omics cohort was developed to expand discovery of the molecular mechanisms underlying health and disease. Here, we report on the AoU multi-omics cohort comprising proteomic (N = 10,043) and transcriptomic (N = 9,043) sequencing data generated from ancestrally diverse AoU participants. We provide comprehensive expression, splicing, and protein quantitative trait locus (e/s/pQTL) analyses and detected 182,246 QTLs, of which 54,255 finemapped to rare variants and 59.4% (32,235) resolve to a single causal variant. We provide multiple insights into rare variant effects and demonstrate that they are more likely to be ancestrally-restricted, replicate across molecular layers and impact known Mendelian disease genes (OR = 1.4) and approved drug targets (OR = 1.3). Rare variant QTLs from AoU further provided evidence for 5,186 variants, many absent from ClinVar, affecting established disease genes. Combined, the availability of multi-omics in AoU provides a key resource to identify the genetic and molecular mechanisms impacting health and disease across multiple ancestry groups in the United States.